Zobrazeno 1 - 10
of 89
pro vyhledávání: ''
Autor:
Günter Fingerle-Rowson, Ekaterina Gibiansky, Michael Brewster, Vincent Buchheit, Candice Jamois, Nicolas Frey, Leonid Gibiansky
Publikováno v:
British Journal of Clinical Pharmacology
Aims Rituximab is standard care in a number of lymphoma subtypes, including follicular lymphoma (FL), although many patients are resistant to rituximab, or develop resistance with repeated treatment, and a high proportion relapse. Obinutuzumab is a n
Publikováno v:
British Journal of Clinical Pharmacology
Aims Quizartinib is an oral, highly potent and selective next-generation FMS-like tyrosine kinase 3 (FLT3) inhibitor under investigation in patients with FLT3-internal tandem duplication-mutated acute myeloid leukaemia. This drug-drug interaction stu
Autor:
Julie Errington, Gareth J. Veal, Alan V. Boddy, Ruth Ladenstein, Peter J. Shaw, Christa E. Nath, Janna K. Duong
Publikováno v:
British Journal of Clinical Pharmacology. 85:136-146
Aims: Carboplatin dosage is calculated by using the estimated glomerular filtration rate (GFR) to achieve a target plasma area under the plasma concentration–time curve (AUC). The aims of the present study were to investigate factors that influence
Autor:
Dave Singh
Publikováno v:
British Journal of Clinical Pharmacology
Fixed dose combination (FDC) dual bronchodilators that co-administer a long acting β2 -adrenoceptor agonist (LABA) and a long acting muscarinic antagonist (LAMA) are a new class of inhaled treatment for chronic obstructive pulmonary disease (COPD).
Publikováno v:
British Journal of Clinical Pharmacology
Aims To evaluate the pharmacokinetics (PK) and pharmacodynamics (PD) of subcutaneous peginterferon beta-1a in patients with relapsing-remitting multiple sclerosis (RRMS) in the phase 3 ADVANCE study (n = 1512). Methods During year 1, patients were ra
Publikováno v:
British Journal of Clinical Pharmacology
Aims The aim was to evaluate the effect of boceprevir and telaprevir on dolutegravir pharmacokinetics (PK); the effect of dolutegravir on boceprevir and telaprevir PK was assessed through comparison with historical data for each hepatitis C virus (HC
Autor:
Andrew H. Wei, Sushrut Patil, Sharon Avery, Andrew Spencer, Lisa Hui, Michael J. Dooley, Meredith Wiseman, Susan Poole, John Coutsouvelis
Publikováno v:
British Journal of Clinical Pharmacology. 75:565-568
Tumour lysis syndrome (TLS) is a life-threatening oncological emergency characterized by hyperuricaemia, hyperkalaemia, hyperphosphataemia, and hypocalcaemia [1, 2] due to the rapid lysis of malignant cells, following the initiation of anticancer the
Publikováno v:
British journal of clinical pharmacology. 8
1 Labetalol was given to 41 hypertensive patients in a divided dosage of 150--2,400 mg daily for periods ranging from 1--64 months. 2 Monotherapy with labetalol was adequate in 12 out of 19 patients with essential hypertension and in 15 out of the 22
Autor:
Naw Thida Zin, François Nosten, Joel Tarning, Warunee Hanpithakpon, Marcus J. Rijken, Rose McGready, Aung Pyae Phyo, Hla Hla Than, Niklas Lindegardh, Nicholas J. White, Nathar Hlaing, Pratap Singhasivanon
Publikováno v:
British Journal of Clinical Pharmacology
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • Lowered plasma concentrations of artesunate have been reported in uncomplicated malaria in pregnancy which could risk the life of the mother and fetus. • The reason for lowered plasma concentrations in p
Publikováno v:
British Journal of Clinical Pharmacology. 69:143-151
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • CP-690,550 is a novel JAK inhibitor in development as a therapy for rheumatoid arthritis. • Methotrexate is the cornerstone of combination treatment for rheumatoid arthritis. • The safety and tolerabil